Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $350.2 million.

  • Avidity Biosciences' Cash & Equivalents fell 5.40% to $350.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.2 million, marking a year-over-year decrease of 5.40%. This contributed to the annual value of $219.9 million for FY2024, which is 18.79% up from last year.
  • Latest data reveals that Avidity Biosciences reported Cash & Equivalents of $350.2 million as of Q3 2025, which was up 43.58% from $243.9 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Cash & Equivalents peaked at $575.8 million during Q2 2024, and registered a low of $85.7 million during Q3 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $243.9 million (2025), whereas its average is $275.3 million.
  • In the last 5 years, Avidity Biosciences' Cash & Equivalents plummeted by 64.95% in 2022 and then surged by 332.21% in 2024.
  • Over the past 5 years, Avidity Biosciences' Cash & Equivalents (Quarterly) stood at $320.4 million in 2021, then rose by 6.23% to $340.4 million in 2022, then crashed by 45.63% to $185.1 million in 2023, then grew by 18.79% to $219.9 million in 2024, then dropped by 5.40% to $350.2 million in 2025.
  • Its last three reported values are $350.2 million in Q3 2025, $243.9 million for Q2 2025, and $254.2 million during Q1 2025.